RT Journal Article
T1 Pathogenic mechanisms involving the interplay between adipose tissue and auto-antibodies in rheumatoid arthritis.
A1 Arias-de la Rosa, Ivan
A1 Escudero-Contreras, Alejandro
A1 Ruiz-Ponce, Miriam
A1 Cuesta-Lopez, Laura
A1 Roman-Rodriguez, Cristobal
A1 Perez-Sanchez, Carlos
A1 Ruiz-Limon, Patricia
A1 Ruiz, Rocio Guzman
A1 Leiva-Cepas, Fernando
A1 Alcaide, Juan
A1 Segui, Pedro
A1 Plasencia, Chamaida
A1 Martinez-Feito, Ana
A1 Font, Pilar
A1 Abalos, María C
A1 Ortega, Rafaela
A1 Malagon, Maria M
A1 Tinahones, Francisco J
A1 Collantes-Estevez, Eduardo
A1 Lopez-Pedrera, Chary
A1 Barbarroja, Nuria
K1 Health sciences
K1 Immunology
K1 Rheumatology
AB We aimed to evaluate the association between adipose tissue (AT) dysfunction, autoimmunity, and disease activity in rheumatoid arthritis (RA). A cross-sectional study including 150 RA patients and 50 healthy donors and longitudinal study with 122 RA patients treated with anti-tumor necrosis factor (TNF)-α, anti-interleukin 6 receptor (IL6R) or anti-CD20 therapies for 6 months were carried out. In vitro experiments with human AT and adipocyte and macrophage cell lines were performed. A collagen-induced arthritis mouse model was developed. The insulin resistance and the altered adipocytokine profile were associated with disease activity, the presence of anti-citrullinated proteins anti-bodies (ACPAs), and worse response to therapy in RA. AT in the context of arthritis is characterized by an inflammatory state alongside the infiltration of macrophages and B/plasmatic cells, where ACPAs can have a direct impact, inducing inflammation and insulin resistance in macrophages and promoting a defective adipocyte differentiation, partially restored by biologicals.
PB Cell Press
YR 2022
FD 2022-08-03
LK http://hdl.handle.net/10668/22278
UL http://hdl.handle.net/10668/22278
LA en
NO Arias-de la Rosa I, Escudero-Contreras A, Ruiz-Ponce M, Cuesta-López L, Román-Rodríguez C, Pérez-Sánchez C, et al. Pathogenic mechanisms involving the interplay between adipose tissue and auto-antibodies in rheumatoid arthritis. iScience. 2022 Aug 6;25(9):104893
NO We thank all the patients for their kind participation in this study. This research was funded by grants from the Institute of Health Carlos III, ISCIII (PI17/01316, PI20/00079, PI21/005991, and RICOR-RD21/0002/0033), co-financed by the European Regional Development Fund (ERDF), a way to make Europe, Spain, MINECO (RyC-2017-23437), the Andalusian Foundation of Rheumatology (FAR) and Consejerı´a de Conocimiento, Investigación y Universidad, Junta de Andalucı´a (P20_01367). C.L.-P. was supported by a contract fromthe Junta de Andalucia (Nicolas Monardes program). J.A. was supported by a ‘‘PFIS’’ predoctoral contract (FI19/00177). P.R.L. was supported by a ‘‘Sara Borrell’’ postdoctoral contract (CD19/00216) from the ISCIIIMadrid (Spain), co-financed by the Fondo Europeo de Desarrollo Regional-FEDER.
DS RISalud
RD Apr 5, 2025